Biology:Evogliptin
From HandWiki
Short description: Chemical compound
Clinical data | |
---|---|
Trade names | Suganon |
Other names | DA-1229 |
Routes of administration | By mouth |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H26F3N3O3 |
Molar mass | 401.430 g·mol−1 |
3D model (JSmol) | |
| |
|
Evogliptin (INN; trade names Suganon, Evodine) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.[1] It was developed by the South Korea n pharmaceutical company Dong-A ST and is approved for use in South Korea[2] and Russia.[3] In a meta-analysis involving data from 6 randomized controlled trials (887 patients), Dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin. [4]
References
- ↑ "Evogliptin: First Global Approval". Drugs 75 (17): 2045–9. November 2015. doi:10.1007/s40265-015-0496-5. PMID 26541763.
- ↑ "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015. https://www.pipelinereview.com/index.php/2015100259148/Small-Molecules/Dong-A-STs-DPP4-inhibitor-SUGANON-got-approved-for-type-2-diabetes-in-Korea.html.
- ↑ "Evodine (evogliptin) film-coated tablets. Full prescribing information" (in Russian). http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=6c9be7e5-6693-4b07-9f31-0175437b053e&t=.
- ↑ "Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis.". Indian J Endocrinol Metab 24 (5): 434–445. Nov 2020. doi:10.4103/ijem.IJEM_418_20. PMID 33489850.
Original source: https://en.wikipedia.org/wiki/Evogliptin.
Read more |